AstraZeneca and Merck's string of Lynparza successes ends in ovarian cancer

AstraZeneca and Merck & Co. on Thursday said a combination of their cancer drug Lynparza and an experimental drug called cediranib failed to keep relapsed ovarian cancer patients' disease in check better than standard chemotherapy.